Precision healthcare is making a significant impact in Qatar, specifically in the prevention of breast and ovarian cancer. A recent study conducted by the Qatar Precision Health Institute’s (QPHI) Qatar Biobank identified 22 participants with genetic mutations that increase the risk of developing these types of cancer. These individuals were referred to the Hamad Medical Corporation’s (HMC) National Centre for Cancer Care for proactive treatment, even before any symptoms appeared. According to Dima Darwish, Head of Genomic Education at QPHI, this research has saved the lives of these 22 participants.
The BRCA Gene Mutations study carried out by QPHI focuses on genetic predispositions to breast and ovarian cancers among Qatar’s population. This study has contributed to advancements in personalized medicine and cancer prevention strategies by identifying individuals who have a higher chance of developing these types of cancer due to mutations in the BRCA1 and BRCA2 genes. These genes, commonly known as ‘breast cancer susceptibility genes’, produce proteins that help suppress tumors. When mutated, these genes can lead to uncontrolled cell growth and the formation of tumors, significantly increasing the risk of developing breast and ovarian cancers.
Individuals who inherit mutations in the BRCA1 or BRCA2 genes have a higher risk of developing breast and ovarian cancers compared to those without these mutations. Through whole-genome analysis, the Qatar Biobank was able to identify individuals with the variant for the mutated gene, indicating a high possibility of developing breast or ovarian cancer. By referring these individuals to the NCCCR for early prevention and treatment, all 22 participants were cured even before the disease had a chance to start. This proactive approach to healthcare has proven to be lifesaving for those at high risk of developing breast and ovarian cancer.
Dima Darwish emphasized the importance of continuing the BRCA study to identify individuals with hereditary risk factors for breast and ovarian cancer. By analyzing the entire genome of participants, researchers can detect genetic mutations that may predispose individuals to these types of cancers. This ongoing research will enable healthcare providers to offer personalized preventative care and treatment plans to individuals at risk, ultimately saving lives through early intervention.
The success of the precision healthcare approach in Qatar highlights the importance of genetic testing and personalized medicine in cancer prevention. By identifying individuals with genetic mutations that increase the risk of developing breast and ovarian cancer, healthcare providers can offer proactive treatment options that can prevent the onset of the disease. The collaboration between QPHI, Qatar Biobank, and NCCCR has resulted in life-saving interventions for 22 participants, demonstrating the power of precision healthcare in improving health outcomes.
Moving forward, QPHI plans to continue its research into BRCA gene mutations and other genetic predispositions to cancer in Qatar’s population. By expanding their knowledge of genetic risk factors and developing targeted prevention strategies, researchers can further enhance the effectiveness of precision healthcare in preventing and treating cancer. The success of the BRCA study serves as a testament to the potential of personalized medicine in revolutionizing healthcare and saving lives in Qatar and beyond.
